Epidermal Growth Factor Receptor Pathway

The epidermal growth factor (EGF) family of receptor tyrosine kinases (RTKs) is made up of four receptors:

  • EGFR (erb1)
  • HER2 (erb2)
  • HER3 (erb3)
  • HER4 (erb4)

Members of EGFR Family

Members of the EGF-R family contain a single transmembrane domain, a cytoplasmic tyrosine kinase domain, and an extracellular domain that is involved in receptor dimerization and ligand binding.

Binding of an extracellular ligand or due to environmental stimuli, like ultraviolet light, will induce EGFR to form homo- or hetero-dimers with other family members which activates its intracellular tyrosine kinase domain and autophosphorylate its C-terminal tyrosine residues.

Transduction by activated EGFR results in downstream effects on proteins such as phosphatidyl 3-kinase (PI3-K), Akt, Ras, Raf , Phospholipase C-γ(PLC-γ1), and mitogen-activated protein kinase (MAPK). These entities are associated with cell proliferation, survival and motility.


EGFR/RTKs and its downstream signaling cascades have become prominent targets for therapeutic intervention because of their involvement in many types of cancers. BioVision provides a number of antibodies, small molecular inhibitors, recombinant proteins, and ELISA assay kits to examine this signaling pathway.

Key Features

  • Highly pure and active recombinant proteins
  • Simple and easy-to-use ELISA kits
  • Tested and validated antibodies
  • Highly potent, selective and many inhibitor options to choose from
  • Small molecule inhibitors targeting different components of the EGF signaling pathway

About BioVision Incorporated

BioVision, Inc., is a privately held Life Science company headquartered in the beautiful San Francisco Bay Area.

BioVision develops and offers a wide variety of products including assay kits, antibodies, recombinant proteins & enzymes, and other innovative research tools for studying Apoptosis, Metabolism, Cell Proliferation, Cellular Stress, Cell Damage and Repair, Diabetes, Obesity and Metabolic Syndrome, Stem Cell Biology, Gene Regulation, Signal Transduction, etc. BioVision's products are currently being sold in more than 60 countries worldwide.

Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.

Last updated: Feb 21, 2020 at 9:30 AM


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    BioVision Incorporated. (2020, February 21). Epidermal Growth Factor Receptor Pathway. News-Medical. Retrieved on September 23, 2021 from https://www.news-medical.net/whitepaper/20190523/Epidermal-Growth-Factor-Receptor-Pathway.aspx.

  • MLA

    BioVision Incorporated. "Epidermal Growth Factor Receptor Pathway". News-Medical. 23 September 2021. <https://www.news-medical.net/whitepaper/20190523/Epidermal-Growth-Factor-Receptor-Pathway.aspx>.

  • Chicago

    BioVision Incorporated. "Epidermal Growth Factor Receptor Pathway". News-Medical. https://www.news-medical.net/whitepaper/20190523/Epidermal-Growth-Factor-Receptor-Pathway.aspx. (accessed September 23, 2021).

  • Harvard

    BioVision Incorporated. 2020. Epidermal Growth Factor Receptor Pathway. News-Medical, viewed 23 September 2021, https://www.news-medical.net/whitepaper/20190523/Epidermal-Growth-Factor-Receptor-Pathway.aspx.

Other White Papers by this Supplier